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A number of studies have recently demonstrated
that homocysteine is an independent risk factor for
atherosclerosis and thrombosis. Although severe
hyperhomocysteinemia is rare, mild hyperhomocys-
teinemia occurs in approximately 5% to 7% of the
general population.1,2
In in vitro studies, homocysteine has been shown
to cause endothelial dysfunction at several levels by
depressing the activation of protein C,3 by inhibiting
the expression of heparan sulphate,4 and by inducing
the expression of tissue factor.5 Homocysteine-
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Purpose: In vitro studies have recently demonstrated that homocysteine interacts with the
aortic wall by inducing both elastolysis and endothelial perturbation. The aim of this study
was to evaluate homocysteine plasma levels and their relationships with aortic diameter and
endothelial damage in patients with abdominal aortic aneurysm.
Subjects and Methods: Fifty-eight consecutive male patients (mean age, 69.5 ± 6.6 years; age
range, 49-78 years) who underwent abdominal aortic aneurysm surgery were enrolled in
the study. Twenty-two of 58 patients had no clinical or instrumental evidence of athero-
sclerosis. Sixty control subjects were age matched and sex matched with the patients. In all
of the subjects, we evaluated total homocysteine and thrombomodulin plasma levels and the
distribution of the C677T methylenetetrahydrofolate reductase gene mutation.
Results: Hyperhomocysteinemia was found in 26 (48%) of the 58 patients with abdominal
aortic aneurysm, and homocysteine plasma levels were significantly higher in patients than
in control subjects (15.7 ± 6.5 µmol/L vs 9.6 ± 3.9 µmol/L; P < .0001). In addition, the
subgroup of patients with abdominal aortic aneurysm who did not show evidence of athero-
sclerosis showed homocysteine plasma levels significantly higher than those in the controls
(14.8 ± 6.1 µmol/L vs 9.6 ± 3.9 µmol/L; P < .001). A larger aneurysmal size was detect-
ed in hyperhomocysteinemic patients than in those with normal homocysteine plasma levels
(5.09 ± 0.84 cm vs 5.79 ± 1.5 cm; P < .05). The genotype distribution of the C677T meth-
ylenetetrahydrofolate reductase mutation was as follows: TT 21%, TC 55%, and CC 24% in
the patients; TT 10%, TC 58%, and CC 32% in the controls. Moreover, in patients a signif-
icant correlation (P < .005) between homocysteine plasma level and 677TT methylenete-
trahydrofolate reductase genotype was found. Thrombomodulin plasma levels were signifi-
cantly higher (P < .00005) in patients (median, 30 ng/mL; range, 10-164 ng/mL) than in
controls (median, 19 ng/mL; range, 13-44 ng/mL), and thrombomodulin levels were sig-
nificantly higher (P < .005) in hyperhomocysteinemic patients (median, 39.5 ng/mL; range,
15-164 ng/mL) than in normohomocysteinemic patients (median, 27.5 ng/mL; range, 10-
85 ng/mL). In addition, in patients with abdominal aortic aneurysm, a direct significant
correlation (P < .005) was found between homocysteine and thrombomodulin.
Conclusions: These data indicate an association between the presence of AAA in patients
selected for surgical treatment of AAA and elevated homocysteine plasma levels and suggest
that homocysteine may induce endothelial perturbation and stimulation in these patients. (J
Vasc Surg 2000;32:531-6.)
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induced endothelial perturbation has also been esti-
mated by increased levels of von Willebrand factor
and thrombomodulin plasma levels in hyperhomo-
cysteinemic subjects.6 Moreover, homocysteine in
vitro impairs the production of nitric oxide and pro-
motes lipid peroxidation.7 This homocysteine-
induced disturbance in oxidative metabolism leads
to overproduction of oxidative radicals that are able
to induce intimal injury, activate elastase, and
increase calcium deposition.8,9
A recent in vitro study demonstrated that homo-
cysteine induces the synthesis of a serine elastase in
arterial smooth muscle cells.10 Experiments in animal
models showed that homocysteine induces elastolysis
in arterial media through the activation of matrix
metalloproteinase-2 (MMP-2).11 Furthermore, a
decreased elastin content and a marked elastinolytic
activity in aortic sections of patients with abdominal
aortic aneurysm (AAA) have been shown.12 At pre-
sent, few data reporting homocysteine plasma levels
in patients with AAA are available.13
Several factors, including vitamins, age, and hor-
mones, influence homocysteine plasma levels; however,
mutations in genes codifying for enzymes involved in
methionine metabolism, such as the C677T methyl-
enetetrahydrofolate reductase (MTHFR) gene muta-
tion, also play an important role. To the best of our
knowledge, the prevalence of this mutation in patients
with AAA is unknown. 
The purpose of this study was to evaluate homo-
cysteine and thrombomodulin plasma levels and the
prevalence of C677T MTHFR mutation in patients
with AAA and to determine whether this mutation
influences homocysteine plasma levels.
METHODS
Subjects. Data on 58 consecutive male patients
(mean age, 69.5 ± 6.6 years; age range, 49-78 years)
who underwent AAA surgery at the Department of
Vascular Surgery of the University of Florence from
June to December 1998 were collected and includ-
ed in the present study.
Hypertension was defined as systolic blood pres-
sure higher than 140 mm Hg or diastolic pressure
higher than 90 mm Hg. Hypercholesterolemia was
defined as cholesterol plasma levels higher than 200
mg/dL, and hypertriglyceridemia as triglyceride
plasma levels higher than 200 mg/dL.
Sixty control subjects were age and sex matched
with the patients with AAA.
Diagnostic assessment. In all of the patients
and in all but six of the control subjects, ultrasound
scanning examination was performed by trained,
skilled sonographers using an Acuson Sequoia Color
Duplex System (Mountain View, Calif) with 7.5-
MHz linear (carotid and arterial limbs) and 5-MHz
convex (aortic) probes.
Common carotid, bulb, and internal carotid
arteries on both sides were explored in longitudinal
and transverse projections. Quantification of steno-
sis included a combination of the information
obtained from B-mode ultrasound scanning imaging
and Doppler scanning velocity analysis. Degree of
stenosis was calculated from the ratio of the residual
lumen of the carotid artery to the estimated normal
bulb diameter (European carotid surgery trial
method). Peak systolic velocity and end diastolic
velocity were criteria for the determination of hemo-
dynamic carotid stenosis.
We studied both abdominal aorta and iliac arter-
ies, noting whether thrombus was present when the
vessel’s diameter, plaque’s thickness, wall’s thick-
ness, and residual lumen extension were measured.
Gray-scale B-mode images of the abdominal aorta
were obtained in both transverse and longitudinal
projections. The common, profunda, and superficial
femoral artery, popliteal artery, posterior tibial
artery, and pedidia artery were evaluated in trans-
verse and longitudinal projections with duplex scan-
ning imaging.
The presence of lower limb arterial disease was
identified by the ankle/brachial pressure index.
Peripheral vascular disease was documented as pre-
sent if the ankle/brachial pressure index was less
than 0.9. Cardiac stress testing and thallium scintig-
raphy were performed in those patients who were
referred for angina symptoms (typical or atypical).
In 22 of 58 patients with AAA and in all control
subjects, there was no clinical evidence of coronary
artery disease (ie, there were no typical or atypical
angina symptoms, and no or minimal intimal change
of the carotid or peripheral arteries was detected by
means of echocolor Doppler scanning). Aneurysmal
size was measured by means of computed tomography.
Blood sampling. Blood withdrawal was performed
between 7:30 AM and 9:00 AM after overnight fasting.
After the first milliliter was discarded, blood was col-
lected in tubes containing 0.109 mol/L trisodium cit-
rate (1:10 volume in volume) and in tubes containing
4.4 mmol/L ethylenediamine tetraacetic acid 2K+ for
thrombomodulin determination and homocysteine
determination, respectively, and immediately placed on
ice. Plasma was separated within 1 hour and stored at
–80°C until the thrombomodulin and homocysteine
determinations. White blood cells from the same
samples were stored at –80°C until DNA extraction.
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Homocysteine measurement. Total homocys-
teine (free and protein bound) plasma levels were
determined by means of high-performance liquid
chromatography (LKB 2248 pump, Pharmacia,
Uppsala, Sweden) and fluorescence detection (fluo-
rescence detector model 474, Waters, Milford,
Mass), according to a modification of the method of
Araki and Sako.14 In brief, 100 µL of plasma was
incubated with 10 µL of 10% tri-n-butylphosphine in
dimethylformamide at 4°C for 30 minutes to reduce
homocysteine and mixed disulphide and deconjugate
homocysteine from plasma proteins. Then, 100 µL
of 0.6 mol/L solution of trichloroacetic acid in 1
nmol/L EDTA 2Na was added. The mixture was
kept for 10 minutes at room temperature and then
centrifuged in an Eppendorf microcentrifuge
(Eppendorf Scientific, Inc, Westbury, NY) at 10,000
rpm for 5 minutes. After 60-minute incubation in a
60°C water bath, aliquots were cooled to room tem-
perature and injected in high-performance liquid
chromatography. Separation was carried out at room
temperature at a flow rate of 1.2 mL/min.
Thrombomodulin determination. Thrombom-
odulin plasma levels were measured by means of a
commercial kit (Asserachrom, Diagnostica Stago,
Asnières-sur-Seine, France).15 The intra-assay and
interassay coefficients were 6.2% and 8.1%, respectively.
DNA extraction. Genomic DNA was extracted
from peripheral blood cells according to the method
of Sambrook et al.16
C677T MTHFR gene mutation detection.
The C677T MTHFR mutation was detected by
means of polymerase chain reaction amplification17
of the MTHFR gene through use of the following
primers: 
5´-TGAAGGAGAAGGTGTCTGCGGG-3´
5´-AGGACGGTGCGGTGAGAGTG-3´
Then 5 mL of the polymerase chain reaction prod-
uct was digested with Hinf I according to the manu-
facturer’s protocol (Amersham, Arlington Heights, Ill)
in a final volume of 20 µL. After digestion, samples
were loaded on an 8% polyacrylamide gel, and DNA
fragments were visualized with ethidium bromide.
Statistical analysis. Hardy-Weinberg equilibri-
um was assessed through χ2 analysis.
Unless otherwise indicated, the results are
given as means ± SD. Because of the skewed distri-
bution of plasma thrombomodulin, the thrombo-
modulin plasma levels were reported in terms of
medians and ranges.
The Fisher exact test was used for comparisons
between single groups. The Spearman rank correla-
tion coefficient was used for correlation analysis. The
nonparametric Mann-Whitney test for unpaired data
was used for comparisons between single groups.
Analysis of variance, followed by post hoc Scheffé
testing, was used to evaluate the association between
homocysteine levels and MTHFR genotypes.
Univariate logistic analysis was performed to deter-
mine the association between hyperhomocysteinemia
and AAA or between hyperhomocysteinemia and aor-
tic enlargement; to adjust for other AAA risk factors,
multivariate logistic regression analysis was used.
Probability values of less than .05 are considered
statistically significant.
RESULTS
Characteristics of the patients and control sub-
jects are reported in Table I.
Homocysteinemia and C677T MTHFR gene
mutation and genotype distribution. Mean
homocysteine plasma levels in patients with AAA
were higher than in control subjects (15.7 ± 6.5
µmol/L vs 9.6 ± 3.9 µmol/L; P < .0001). In addi-
tion, patients with AAA with no evidence of athero-
sclerotic localization showed homocysteine plasma
levels higher than those in control subjects (14.8 ±
6.1 µmol/L vs 9.6 ± 3.9 µmol/L; P < .001).
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Table I. Characteristics of subjects investigated
AAA group Control group
No. of patients 58 60
Age (y) 69.3 ± 6.7 67.6 ± 7.0
Smokers 27 (47%) 18 (30%)
Hypertension 34 (59%) 2 (3%)
Diabetes mellitus 7 (12%) –
Hypercholesterolemia 26 (45%) 2 (3%)
Hypertriglyceridemia 14 (24%) 3 (5%)
Distribution of homocysteine plasma levels in patients
with AAA and controls.
Hyperhomocysteinemia, defined as homocys-
teine plasma levels above the 95th percentile of the
control subjects (15.5 µmol/L), was detected in 26
(48%) of the 58 patients (P < .0001; Figure).
Homocysteine plasma levels in smokers versus
nonsmokers were as follows: 14.4 ± 6.3 µmol/L vs
16.8 ± 6.6 µmol/L in patients; 10.8 ± 4.9 µmol/L
vs 9.6 ± 3.2 µmol/L in controls.
Univariate logistic analysis showed a significant
association between hyperhomocysteinemia and
AAA (OR = 23.3; CI = 5.2-105; P = .0007).
Adjustment for the classic risk factors for cardiovas-
cular disease, such as hypertension, smoking habit,
and dyslipidemia, did not significantly alter this
result (OR = 6; CI = 1.23-29.6; P = .029).
The C677T MTHFR genotype distribution in
the patients with AAA and the controls is reported
in Table II. The percentage of subjects showing a
TT genotype was higher in the patients than in the
controls (21% vs 10%), although it did not reach sta-
tistical significance. In addition, the T allele fre-
quency was higher in the patients with AAA than in
the controls (0.48 vs 0.39), but the difference was
not significant.
In patients with AAA, there was a significant rela-
tionship between MTHFR genotype and homocys-
teine plasma levels (Table II). Mutant homozygotes
had higher mean homocysteine plasma levels than
did the other genotypes in both patients and con-
trols, but only in the patients with AAA were the dif-
ferences statistically significant (P < .005; Table II).
Aneurysmal size and homocysteinemia. The
aneurysmal size was significantly greater (P = .019;
Table III) in patients with hyperhomocysteinemia
than in patients with normal homocysteine plasma
levels. 
In patients with homocysteine plasma levels
higher than those in the 95th percentile of the con-
trol group, after adjustment for hypertension, an
OR of 4.0 (CI = 1.2-13.5; P = .026) for an aortic
diameter larger than 6 cm was found.
No significant correlation (P = .41) was found
between age and aneurysmal size in the patients with
AAA. The aneurysmal size was not related to the
duration of the presence of AAA, to blood pressure
control, or to the use of β blockers.
Homocysteine and thrombomodulin plasma
levels. Patients with AAA showed thrombomodulin
levels significantly higher (median, 30 ng/mL;
range, 10-164 ng/mL) than those in the controls
(median, 19 ng/mL; range, 13-44 ng/mL; P <
.00005).
A direct significant correlation between throm-
bomodulin and homocysteine in patients with AAA
was detected (P < .05; r = 0.31).
Median thrombomodulin plasma levels were
39.5 ng/mL (range, 15-164 ng/mL) in hyperho-
mocysteinemic patients with AAA and 27.5 ng/mL
(range, 10-85 ng/mL) in normohomocysteinemic
patients, the difference being statistically significant
(P < .005). Thrombomodulin levels higher than
those in the controls were also found in the sub-
group of patients with AAA without evidence of ath-
erosclerotic disease (38 ng/mL [range, 14-106
ng/mL] vs 19 ng/mL [range, 13-44 ng/mL]; P <
.00005).
DISCUSSION
The current study shows an association between
homocysteine plasma levels and AAA in patients
who underwent AAA surgery. Interestingly, the
association was also observed in the subgroup of
patients without clinical and instrumental manifesta-
tions of atherosclerosis. The presence of underlying
vascular alterations and atherosclerotic disease can-
not be entirely ruled out in this subset of patients, in
whom the degenerative rather than the proliferative
and synthetic response, leading to the formation of
atheroma, might be prevalent. 
In this study, the aortic diameter in patients with
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Table II. C677T MTHFR genotype distribution
and homocysteine plasma levels in patients with
AAA and controls
Plasma homocysteine
Genotype n (%) (µmol/L)
Patients with AAA 58
TT 12 (21) 22.0 ± 8.6*
TC 32 (55) 14.8 ± 4.8
CC 14 (24) 12.2 ± 4.0
Controls 60
TT 6 (10) 11.6 ± 2.6
TC 35 (58) 9.4 ± 4.4
CC 19 (32) 9.3 ± 2.9
*TT vs TC and TT vs CC: P < .005.
Table III. Aneurysmal size and hyperhomocys-
teinemia in patients with AAA 
No. of Plasma Mean aortic diameter
subjects homocysteine (cm)
32 < 95th percentile of controls 5.09 ± 0.84 
26 > 95th percentile of controls 5.79 ± 1.5*
*P < .05.
AAA was significantly larger in the subgroup with
hyperhomocysteinemia than in normohomocys-
teinemic patients, and this correlation remained sig-
nificant after adjustment for hypertension.
The etiology of AAA is largely unknown; the
condition is thought to be multifactorial. AAA
shares some characteristics and risk factors with ath-
erosclerosis, but epidemiologic differences between
patients with obstructive vascular and aneurysmal
disease have been reported, and a possible role for
specific genetic factors has been suggested.18,19
Homocysteine may thus be part of the cause of AAA
in some people.
There are a number of pathophysiologic mecha-
nisms that might explain the association observed in
this study. In the normal vessel wall, elastin and col-
lagen act as a strong, almost indistensible safety net;
aneurysm and eventual rupture occur only with fail-
ure of this safety net. Reduced amounts of tissue
inhibitors of MMPs have been demonstrated within
the human aneurysmal wall.20 In vitro, homocys-
teine is able to activate the zymogen pro-MMP-2 to
the active form MMP-2.11 In addition, in minipigs
the elastin content of arteries cultivated with homo-
cysteine was decreased and was associated with an
increase of MMP-2 activity; the alterations of the
elastic structure were similar to those observed in
hyperhomocysteinemic animals.11
Davis et al21 observed that MMP-2 and MMP-9
are increased in both arteriosclerotic occlusive dis-
ease and AAA. In addition, there was increased acti-
vation and matrix binding of MMP-2 in AAA tissue,
suggesting the participation of this protease in
degradation of the medial elastin and fibrillar colla-
gen of the aorta in the evolution of the disease.21
Homocysteine, at concentrations currently
encountered in hyperhomocysteinemic patients, has
been demonstrated to induce the synthesis of serine
elastase in arterial smooth muscle cells.10 Through a
serine elastase activation, homocysteine increases the
degradation of the extracellular matrix and the
release of elastin peptides that are chemotactic for
vascular smooth muscle cells.22 Moreover, in hyper-
homocysteinemic patients with AAA, homocysteine
might induce an augmented elastase activity that
could account for the larger aortic diameter.
With respect to endothelial function, soluble
thrombomodulin has been found to be elevated in
patients with AAA, both uncomplicated and compli-
cated, as observed by Blann et al.23 The association
between homocysteine and thrombomodulin sug-
gests that hyperhomocysteinemia may induce
endothelial stimulation and perturbation even in the
absence of atherosclerotic disease. However, other
mechanisms, such as an increased concentration of
blood clotting activation products, may be responsi-
ble for endothelial perturbation.
In this study, homocysteine plasma levels in
patients with AAA were correlated with the geno-
type and frequency of C677T MTHFR gene muta-
tion; the prevalence of this mutation was higher than
in the controls, but it did not reach a statistical sig-
nificance, probably because of the small sample size.
Homocysteine levels are affected by different fac-
tors, which prompt speculative considerations. The
higher concentrations of homocysteine in males24,25
may contribute to the clear-cut difference in preva-
lence between the sexes. Higher homocysteine levels
have been reported in smokers in comparison with
nonsmokers, possibly because of lower pyridoxal
phosphate and folate.25,26 Finally, polymorphisms of
genes involved in methionine metabolism influence
homocysteine plasma levels, so the high frequency of
C677T mutation may represent an additional factor
in the familial clustering of the aneurysmal patho-
sis.27 In this study, a minimal effect of smoking on
hyperhomocysteinemia has been observed.
A limitation of this study is the lack of folate and
vitamin B12 levels and von Willebrand factor levels
(as indicators of endothelial perturbation); these
could not be determined in our subjects because of
inadequate blood samples.
Our findings appear at variance with those of
Naydeck et al,13 who did not find any association
between homocysteine and AAA, but this discrepan-
cy may stem from the confounding effect of age
(their subjects were older) and from the insufficient
sample size of the previous report.
In conclusion, our data indicate an association
between the presence of AAA in patients selected for
surgical treatment of AAA and elevated homocys-
teine plasma levels. Larger studies are needed to
confirm the role of hyperhomocysteinemia in AAA
and to evaluate the usefulness of investigating
homocysteine metabolism in patients and perhaps in
their relatives.
REFERENCES
1. Ueland PM, Refsum H. Plasma homocysteine, a risk factor
for vascular disease: plasma levels in health, disease, and drug
therapy. J Lab Clin Med 1989;114:473-501.
2. McCully KS. Homocysteine and vascular disease. Ann Rev
Nutr 1992;12:279-98.
3. Rodgers GM, Conn MT. Homocysteine, an atherogenic
stimulus, reduces protein C activation by arterial and venous
endothelial cells. Blood 1990;75:895-901.
4. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a throm-
bogenic agent, suppresses anticoagulant heparan sulphate
JOURNAL OF VASCULAR SURGERY
Volume 32, Number 3 Brunelli et al 535
expression in cultured porcine aortic endothelial cells. J Clin
Invest 1993;92:1381-6.
5. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers
GM. Homocysteine, a risk factor for premature vascular dis-
ease and thrombosis, induces tissue factor activity in endothe-
lial cells. Arterioscl Thromb 1993;13:1327-33.
6. Van den Berg M, Boers GHJ, Franken DG, Blom HJ, van
Kamp GJ, Jakobs C, et al. Hyperhomocysteinemia and
endothelial dysfunction in young patients with peripheral
arterial occlusive deisease. Eur J Clin Invest 1995;25:176-81.
7. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M,
Singel D, et al. Adverse vascular effects of homocysteine are
modulated by endothelium-derived relaxing factor and relat-
ed oxide of nitrogen. J Clin Invest 1993;91:308-18.
8. McCully KS. Chemical pathology of homocysteine, II: car-
cinogenesis and homocysteine thiolactone metabolism. Ann
Clin Lab Sci 1994;24:27-59.
9. McCully KS. Homocysteine metabolism in scurvy, growth
and arteriosclerosis. Nature 1971;231:391-2.
10. Jourdheuil-Rahmani D, Rolland PH, Rosset E, Branchereau
A, Garçon D. Homocysteine induces synthesis of a serine
elatase in arterial smooth muscle cells from multi-organ
donors. Cardiovasc Res 1997;34:597-602.
11. Bescond A, Augier T, Chareyre C, Charpiot P, Garçon D.
Homocysteine-induced elastolysis in arterial media: activa-
tion of MMP2. Neth J Med 1998;58:S56-S57.
12. Campa JS, Greenhalg RM, Powell JT. Elastin degradation in
abdominal aortic aneurysms. Atherosclerosis 1987;65:13-21.
13. Naydeck BL, Sutton-Tyrrel K, Schiller KD, Newman AB,
Kuller LH. Prevalence and risk factors for abdominal aortic
aneurysms in older adults with and without isolated systolic
hypertension. Am J Cardiol 1999;83:759-64.
14. Araki A, Sako Y. Determination of free and total homocys-
teine in human plasma by high-performance liquid chro-
matography with fluorescence detection. J Chromatogr
1987;422:43-52.
15. Amiral J, Adam M, Mimilla F, Larrivaz I, Chambrette B,
Boffa MC. Design and validation of a new immunoassay for
soluble forms of thrombomodulin and studies on plasma.
Hybridoma 1994;13:205-13.
16. Sambrook J, Fritsch EF, Maniatis P. Molecular cloning. A
laboratory manual. New York: Cold Spring Harbour
Laboratory Press; 1989.
17. Abbate R, Sardi I, Pepe G, Marcucci R, Brunelli T, Prisco D,
et al. The high prevalence of thermolabile 5-10 methylenete-
trahydrofolate reductase (MTHFR) in Italians is not associat-
ed to an increased risk for coronary artery disease (CAD).
Thromb Haemost 1998;79:727-30.
18. Tilson MD. Aortic aneurysm and atherosclerosis. Circulation
1992;85:378-9.
19. Lederle FA, Johnson GR, Wilson SE, Chute EP, Littooy FN,
Bandyk D, et al. Prevalence and association of abdominal aor-
tic aneurysm detected through screening. Ann Intern Med
1997;126:441-9.
20. Brophy CM, Marks WH, Reilly JM, Tilson MD. Decreased
tissue inhibitor of metalloproteinases (TIMP) in abdominal
aortic aneurysm tissue: a preliminary report. J Surg Res
1991;50:653-7.
21. Davis V, Persidskaia R, Baca-Regen L, Itoh Y, Nagase H,
Persidsky Y, et al. Matrix metalloproteinase-2 production and
its binding to the matrix are increased in abdominal aortic
aneurysm. Arteriosclr Thromb Vasc Biol 1998;18:1625-33.
22. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E,
Schlegel R, et al. Promotion of vascular smooth muscle cells
growth by homocysteine. A link to atherosclerosis. Proc Natl
Acad Sci U S A 1994;91:6369-73.
23. Blann AD, Devine C, Amiral J, McCollum CN. Soluble
adhesion molecules, endothelial markers and atherosclerosis
risk factors in abdominal aortic aneurysm: a comparison with
claudicants and healthy controls. Blood Coagul Fibrinolysis
1998;9:479-84.
24. Malinow MR, Kang SS, Taylor LM, Wong PWK, Coull B,
Inahara T, et al. Prevalence of hyperhomocysteinemia in
patients with peripheral arterial occlusive disease. Circulation
1989;79:1180-8.
25. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A,
Nordrehaug JE, et al. Total plasma homocysteine and car-
diovascular risk profile: the Hordaland Homocysteine Study.
JAMA 1995;274:1526-33.
26. Mansoor MA, Kristensen O, Hervg T, Drablos PA,
Stakkestad JA, Woie L, et al. Low concentrations of folate in
serum and erythrocytes of smokers: methionine loading
decreases folate concentrations in serum of smokers and non-
smokers. Clin Chem 1997;43:219-4.
27. Verloes A, Sakalihasan N, Koulischer L, Limer R. Aneurysm
of the abdominal aorta: familial and genetic aspects in three
hundred thirteen pedigrees. J Vasc Surg 1995;21:646-55.
Submitted Aug 23, 1999; accepted Feb 11, 2000.
JOURNAL OF VASCULAR SURGERY
536 Brunelli et al September 2000
AVAILABILITY OF JOURNAL BACK ISSUES
As a service to our subscribers, copies of back issues of Journal of Vascular Surgery for the preceding
5 years are maintained and are available for purchase from Mosby until inventory is depleted. The fol-
lowing quantity discounts are available: 25% off on quantities of 12 to 23, and one third off on quanti-
ties of 24 or more. Please write to Mosby, Subscription Customer Service, 6277 Sea Harbor Dr,
Orlando, FL 32887, or call 800-654-2452 or 407-345-4000 for information on availability of particu-
lar issues. If unavailable from the publisher, photocopies of complete issues may be purchased from Bell
& Howell Information and Learning, 300 N Zeeb Rd, Ann Arbor, MI 48106-1346, or call 734-761-
4700 or 800-521-0600.
